Synaptogenix (NASDAQ:SNPX – Get Rating) is one of 962 publicly-traded companies in the "Pharmaceutical preparations" industry, but how does it contrast to its rivals? We will compare Synaptogenix to similar companies based on the strength of its earnings, risk, institutional ownership, analyst recommendations, valuation, dividends and profitability.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Synaptogenix and its rivals, as provided by MarketBeat.
Get
Synaptogenix alerts:
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Synaptogenix | 0 | 0 | 1 | 0 | 3.00 |
| Synaptogenix Competitors | 3141 | 13133 | 39362 | 635 | 2.67 |
Synaptogenix presently has a consensus target price of $14.00, indicating a potential upside of 108.96%. As a group, "Pharmaceutical preparations" companies have a potential upside of 106.03%. Given Synaptogenix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Synaptogenix is more favorable than its rivals.
Volatility and Risk
Synaptogenix has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Synaptogenix's rivals have a beta of 0.97, meaning that their average share price is 3% less volatile than the S&P 500.
Valuation and Earnings
This table compares Synaptogenix and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio |
| Synaptogenix | N/A | -$12.61 million | -3.19 |
| Synaptogenix Competitors | $1.83 billion | $243.52 million | -4.11 |
Synaptogenix's rivals have higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
9.1% of Synaptogenix shares are owned by institutional investors. Comparatively, 42.0% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 1.9% of Synaptogenix shares are owned by company insiders. Comparatively, 15.1% of shares of all "Pharmaceutical preparations" companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Synaptogenix and its rivals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Synaptogenix | N/A | -45.23% | -43.73% |
| Synaptogenix Competitors | -3,202.84% | -160.99% | -24.58% |
Summary
Synaptogenix rivals beat Synaptogenix on 7 of the 13 factors compared.
Synaptogenix Company Profile
(Get Rating)
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
